Related Experiment Videos
[Chemotherapy repeated injection via pelvic retroperitoneal cannulation]
1Second Affiliated Hospital, West China University of Medical Sciences, Chengdu.
Zhonghua Fu Chan Ke Za Zhi
|August 1, 1997
Summary
Repeated pelvic retroperitoneal chemotherapy via cannulation is a feasible and effective treatment for lymphatic metastases in gynecologic cancer. This method enhances drug concentration in lymph nodes, leading to cancer cell necrosis with minimal toxicity.
Area of Science:
- Gynecologic Oncology
- Pharmacology
- Surgical Oncology
Context:
- Lymphatic metastases significantly impact gynecologic cancer prognosis.
- Conventional chemotherapy delivery to lymphatic metastases can be challenging.
- Targeted drug delivery to lymph nodes is crucial for effective treatment.
Purpose:
- To evaluate the feasibility and efficacy of repeated pelvic retroperitoneal chemotherapy via cannulation for treating lymphatic metastases in gynecologic cancer.
- To assess drug concentration and pathological changes in lymph nodes following the novel delivery method.
- To determine the safety and potential complications associated with this approach.
Summary:
- Animal and human studies demonstrated successful repeated injection of chemotherapy drugs (5-fluorouracil, thiotepa, methotrexate) into the pelvic retroperitoneal space.
- Significantly higher drug concentrations were achieved in lymph nodes compared to peripheral tissues, with no observed toxicity to surrounding organs.
- Clinical observations showed degeneration and necrosis of metastatic cancer cells within lymph nodes, with no severe adverse effects reported.
Impact:
- This technique offers a potentially more effective and targeted treatment strategy for lymphatic spread in gynecologic malignancies.
- It may improve patient outcomes by increasing local drug efficacy while minimizing systemic toxicity.
- The findings support the feasibility of repeated pelvic retroperitoneal cannulation as a valuable therapeutic option.